scholarly journals Adverse drug reaction and causality assessment scales

Lung India ◽  
2011 ◽  
Vol 28 (2) ◽  
pp. 152 ◽  
Author(s):  
SyedAhmed Zaki
Author(s):  
Srihitha Pendota ◽  
Sre Akshaya Kalyani Surabhineni ◽  
Abhinay Sharma Katnapally ◽  
Dharanija Porandla ◽  
Sandeep Kumar Beemreddy

Adverse drug reaction (ADR) is an unwanted, undesirable effect of medication resulting in mild to severe effect on the patient. This review explains definitions of ADR and it differentiation with adverse drug event, medication error. ADRs may cause increased length of stay or initial reason for admission and are major cause of morbidity and mortality worldwide. Risk factors for ADR occurrence include age, gender, patients with multiple diseases and multiple drug therapy (polypharmacy). ADRs are classified into different types based on the mechanism and onset of reaction. The causal relation between suspected drug and reaction can be assessed by using causality assessment scales. The severity and preventability of ADR can be assessed by severity assessment scale and preventability scale respectively. Clinical Pharmacists play an important role in monitoring and management of ADRs.


Pharmacy ◽  
2018 ◽  
Vol 6 (4) ◽  
pp. 108 ◽  
Author(s):  
Siraj Sundaran ◽  
Anjali Udayan ◽  
Keerthi Hareendranath ◽  
Basil Eliyas ◽  
Babu Ganesan ◽  
...  

Hospital-based adverse drug reaction (ADR) monitoring and reporting programs intend to identify and quantify the risks associated with the use of medicines. To examine the causality, preventability and severity of ADR in a hospital setting; a prospective cohort study on spontaneous ADR reporting was conducted from December 2015 to May 2016. Incidence of ADRs, causality, type, severity and preventability were assessed using necessary assessment scales. The study included 3157 hospitalized individuals, in whom 51 ADRs were detected among 49 patients. The overall incidence of suspected ADRs was found to be 1.6%. According to the causality assessment, most of the ADRs reported were probable (n = 26, 51.0%), and type A (augmented/pharmacological) reactions (n = 39, 76%) were the most common type of ADR found. The majority of ADRs were moderate to severe (n = 35, 68.6%), of which 37.3% were found to be potentially preventable. Predictability was observed in 28 (54.9%) reported ADRs. The prescribed medicines most frequently associated with ADRs were antibiotics, antiepileptics and antihypertensives. This feasibility study was able to highlight the clinical pharmacist’s role in ADR monitoring service and create awareness about the way it could be done to promote safer medication use. Similar ADR reporting programs are necessary to educate and to improve awareness among healthcare professionals in some countries.


2017 ◽  
Vol 123 ◽  
pp. 122-129 ◽  
Author(s):  
Annamaria Mascolo ◽  
Cristina Scavone ◽  
Maurizio Sessa ◽  
Gabriella di Mauro ◽  
Daniela Cimmaruta ◽  
...  

PLoS ONE ◽  
2011 ◽  
Vol 6 (12) ◽  
pp. e28096 ◽  
Author(s):  
Ruairi M. Gallagher ◽  
Jamie J. Kirkham ◽  
Jennifer R. Mason ◽  
Kim A. Bird ◽  
Paula R. Williamson ◽  
...  

2016 ◽  
Vol 30 (5) ◽  
pp. 562-566 ◽  
Author(s):  
Vivek Kataria ◽  
Hueyyoung Wang ◽  
Joyce W. Wald ◽  
Yvonne L. Phan

The American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines consider angiotensin-converting enzyme (ACE) inhibitors as one of the mainstay therapies in the management of heart failure. The widespread use of ACE inhibitors has been associated with several notable adverse effects such as hyperkalemia and an increased serum creatinine. There are no previous reports of alopecia associated with lisinopril use; however, a few previous cases of alopecia associated with other ACE inhibitors exist. This report discusses a case of lisinopril-induced alopecia of a 53-year-old male presenting to our outpatient heart failure clinic with a chief complaint of a new onset of alopecia. Upon evaluation, it was suspected that the patient’s alopecia was likely medication induced by lisinopril; therefore, lisinopril was discontinued and switched to an angiotensin receptor blocker (ARB), losartan potassium. Alopecia resolved in 4 weeks after the therapeutic intervention. Our report suggests that the patient likely experienced a medication-induced alopecia, which was successfully resolved through proper identification and removal of the causative agent. Causality assessment between lisinopril and alopecia was determined using the Naranjo Adverse Drug Reaction Probability Scale—a total score of 6 was achieved and thus identified the adverse drug reaction as probable. Clinicians should be aware of the possibility that lisinopril may be an offending agent in a patient with unexplained alopecia.


2015 ◽  
Vol 6 (3) ◽  
pp. 84 ◽  
Author(s):  
Amer Khan ◽  
MirS Adil ◽  
K Nematullah ◽  
S Ihtisham ◽  
K Aamer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document